C9169 – Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
HCPCS Level II code · C codes: Outpatient PPS (Hospital Outpatient)
HCPCS codeC9169
- Long description
- Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
- Short description
- Inj, nogapendekin pmln 1 mcg
- Pricing indicator
53Statute- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1EOther drugs- Added
- October 1, 2024
- Last change
- January 1, 2025 – No change
- Termination date
- December 31, 2024
Frequently asked questions
What is HCPCS code C9169?
C9169 is a HCPCS Level II code for injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram. It was discontinued on December 31, 2024.
Does Medicare cover C9169?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby C codes
- C9161 – Injection, aflibercept hd, 1 mg
- C9162 – Injection, avacincaptad pegol, 0.1 mg
- C9163 – Injection, talquetamab-tgvs, 0.25 mg
- C9164 – Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
- C9165 – Injection, elranatamab-bcmm, 1 mg
- C9166 – Injection, secukinumab, intravenous, 1 mg
- C9167 – Injection, adamts13, recombinant-krhn, 10 iu
- C9168 – Injection, mirikizumab-mrkz, 1 mg
- C9170 – Injection, tarlatamab-dlle, 1 mg
- C9171 – Injection, pegulicianine, 1 mg
- C9172 – Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
- C9173 – Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
- C9174 – Injection, datopotamab deruxtecan-dlnk, 1 mg
- C9175 – Injection, treosulfan, 50 mg
- C9176 – Tc-99m from domestically produced non-heu mo-99, [minimum 50 percent], full cost recovery add-on, per study dose
- C9248 – Injection, clevidipine butyrate, 1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.